Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-02-21

Study Completion Date

2025-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, with delayed cerebral ischemia (DCI) as a major complication. There are several evidences, both in preclinical and in clinical studies that intraventricular fibrinolysis (IVF) controls the phenomenon that are leading to DCI. Here, the investigators propose to conduct a phase III trial to provide a clear evaluation of the impact of IVF after aneurysmal SAH.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Avoiding Anticoagulation After IntraCerebral Haemorrhage

NCT03243175

Intracerebral Hemorrhage Atrial Fibrillation Microhaemorrhage

RECRUITING PHASE3

Clinical Efficacy of In-situ Thrombolysis in Case of Intraventricular Haemorraghia by Aneurysm Rupture

NCT00823485

Aneurysm, Ruptured Subarachnoid Hemorrhage

COMPLETED PHASE2/PHASE3

Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase

NCT02216565

Stroke, Acute

TERMINATED NA

National Retrospective Study Of Recanalization Treatments In Pediatric Arterial Ischemic Stroke

NCT03887143

Arterial Ischemic Stroke

COMPLETED

Prevention of Venous Thromboembolism in Patients With Acute Primary Intracerebral Hemorrhage

NCT00699465

Intracerebral Hemorrhage

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction: Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, which often causes acute hydrocephalus requiring the insertion of an external ventricular drain (EVD). A major complication of aneurysmal SAH is delayed cerebral ischemia (DCI), which corresponds to the occurrence of an ischemic stroke up to 21 days after the aneurysm rupture. There are currently only few ways to prevent it. As DCI is linked to the presence of blood within the subarachnoid space, it has been hypothesized that removing this blood may decrease the risk of DCI. It could be obtained by injecting a fibrinolytic agent through the EVD, a therapeutic strategy named intraventricular fibrinolysis (IVF). There are several evidences, both in preclinical and in clinical studies that IVF controls the phenomenon that are leading to DCI. It has notably been shown in Phase I and Phase II trial that IVF in aneurysmal SAH is safe and may decrease the risk of DCI, with a trend to improve the rate of good functional outcome by about 10%. Here, the investigators propose to conduct a phase III trial to provide a clear evaluation of the impact of IVF after aneurysmal SAH.

Materials and methods: this study will include patients with aneurysmal SAH requiring external ventricular drainage. The investigators will perform a pragmatic randomized controlled trial: compare the standard of care, i.e. the EVD alone, to the experimental treatment, i.e. IVF, with an open design. After exclusion of the aneurysm, patients will be randomly allocated to receive either EVD alone or EVD+IVF (72 hours, 9 doses). The primary outcome will be the proportion of patients without severe disability 6 months after the aneurysm rupture, as evaluated by the modified Rankin Scale (mRS). The investigators plan to include 440 patients, to show an increase of the rate of good functional outcome of 10% in the EVD+IVF group compared to the EVD alone group (α=0.05 and β=0.8). To obtain such sample, a multicenter trial is mandatory, and to date 16 centers accepted to participate. Each center will include one patient per month, and the inclusion period is to last 48 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subarachnoid Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

We plan to perform a pragmatic randomized controlled trial: compare the standard of care, i.e. the EVD alone, to the experimental treatment, i.e. IVF. As the standard treatment does not include injection within the EVD, the trial will not include injection through the EVD in the control group, so the trial will have an open design.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

To minimize bias, the randomization and the treatment from V0 to the end of treatment will be performed by the local intensivist designed as investigator. The follow-up until day 4 (V1) to 6 months (V4), so the judgement criteria will be collected by the local neurosurgeon designed as investigator, who will be blinded to the treatment received.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EVD alone

In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.

Group Type NO_INTERVENTION

No interventions assigned to this group

EVD + IVF with Alteplase

Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).

Group Type EXPERIMENTAL

EVD + IVF with Alteplase

Intervention Type DRUG

Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EVD + IVF with Alteplase

Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Intraventricular fibrinolysis with Alteplase

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients (age 18-75) with SAH on initial CT-Scan examination.
* SAH associated with hydrocephalus requiring external ventricular drainage.
* Confirmation of an associated intracranial aneurysm by vascular imaging.
* Time from onset to admission under 24 hours.
* Exclusion of the aneurysm by surgical clipping or endovascular coiling before IVF.
* Oral information on research and informed consent of the patient and/or his relatives.

Exclusion Criteria

* Patient with severe clinical presentation on admission: WFNS score = 5.
* Associated intracerebral hematoma of more than 2 cm in its larger width.
* SAH diagnosed on lumbar puncture: original Fisher grade = 1.
* Impossibility to exclude the aneurysm within 72 hours following its rupture.
* Patient previously treated with antiplatelet therapy or treated with antiplatelet therapy after the aneurysm exclusion.
* Severe coagulopathy, including oral vitamin K antagonist.
* Pregnant or lactating woman.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No